Ziccums affärsidé är att utveckla nya beredningar av biologiska läkemedel genom bolagets patenterade teknologi LaminarPace, som utvecklar torra beredningsformer av produkter som i nuläget enbart finns i vätskeform.
Bransch: Sjukvård Marknad: First North Stockholm Tickerkod: ZICC Certified Adviser: Erik Penser Bank
I grafen visas aktiekursutveckling och omsättning för valt bolag. Informationen är fördröjd med 15 min.
Omsättning
Aktuell Kurs
Utvecklingen i dag
Pressreleaser | 19 Jun 2024 | Ziccum
Ziccum signs Evaluation agreement with…
Ziccum AB (publ) has signed an Evaluation Agreement with ReCode Therapeutics, Inc. (ReCode), a US clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and…
Ziccum is continuously engaged in business discussions with potential industrial partners. The status of Ziccum’s project portfolio is presented quarterly in the company interim reports. There are currently further updates…
On 27 April 2021, the Annual General Meeting of Ziccum AB (publ) (”Ziccum” or the ”Company”) resolved on a directed issue of not more than 46,000 employee stock options of…
Ziccum AB (publ) (”Bolaget”) avhöll den 29 maj 2024 årsstämma i Lund. Vid stämman fattades bland annat följande beslut. Fastställande av årsbokslut och ansvarsfrihet Stämman beslutade att fastställa resultat- och…
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Ziccum AB (publ) (the “Company”) on the 29th of May 2024 in Lund. Adoption of income statement…
Ziccum partners with Dagens Industri, the largest Nordic business paper, to improve shareholders’ access to news updates and raise broader awareness of its continuous scientific and commercial progress. Ziccum AB…
Den 25 april 2024 offentliggjorde Ziccum AB (publ) (”Bolaget”) pressmeddelande innehållande kallelse till Bolagets årsstämma att hållas den 29 maj 2024. I kallelsen angavs att förslag avseende beslut enligt punkterna…
Watch Ziccum CEO Ann Gidner in a comprehensive interview with analyst Jonathan Furelid on the highlights of Ziccum’s Q1 2024 report and the company’s current and coming status. CEO Ann…
Ziccum AB (publ) (‘Ziccum’) has filed three PCT applications with ample and significant data covering years of equipment development and refinement, process parameter knowledge gained, plus key biopharmaceutical formulation expertise…
INTERIM REPORT Q1, 1 JANUARY – 31 MARCH 2024 Significant events during the Quarter Successful outcomes of LaminarPace™ Feasibility study with Biotech partner On January 10, the company announced that,…
Kommande händelser